LinkedIn Profile

Access Light Sciences Oncology historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:lightsciencesoncology 44861 May 29th, 2019 12:00AM Light Sciences Oncology 439 12.00 Open Pharmaceuticals May 29th, 2019 12:34PM May 29th, 2019 12:34PM Light Sciences Oncology (LSO) is developing Aptocine™ (talaporfin sodium) for the treatment of solid tumors as well as other indications such as benign prostatic hyperplasia (BPH). Aptocine is a water-soluble drug energized by a small, single-use, disposable drug activator included with the drug. Aptocine is designed to provide tolerable, effective, and repeatable treatments for patients. LSO has completed treatment in Phase 3 trials of Aptocine in patients with hepatocellular carcinoma (HCC) and patients with metastatic colorectal cancer (MCRC). LSO is also conducting clinical trials of Aptocine in benign prostatic hyperplasia (BPH), or enlargement of the prostate, and is supporting a trial of Aptocine in neurofibromatosis, and has clinical or preclinical programs in cardiovascular disease, eye disease, and dermatology. The Company has positioned Aptocine to benefit an increasing number of patients with a strong portfolio of intellectual property and innovative applications in development. Open Oncology, Ophtalmology, Urology, Cardiovascular, Dermatology Open Light Sciences Oncology Pharmaceuticals & Biotechnology
private:lightsciencesoncology 44861 Feb 17th, 2018 12:00AM Light Sciences Oncology 413 14.00 Open Pharmaceuticals Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM Light Sciences Oncology (LSO) is developing Aptocine™ (talaporfin sodium) for the treatment of solid tumors as well as other indications such as benign prostatic hyperplasia (BPH). Aptocine is a water-soluble drug energized by a small, single-use, disposable drug activator included with the drug. Aptocine is designed to provide tolerable, effective, and repeatable treatments for patients. LSO has completed treatment in Phase 3 trials of Aptocine in patients with hepatocellular carcinoma (HCC) and patients with metastatic colorectal cancer (MCRC). LSO is also conducting clinical trials of Aptocine in benign prostatic hyperplasia (BPH), or enlargement of the prostate, and is supporting a trial of Aptocine in neurofibromatosis, and has clinical or preclinical programs in cardiovascular disease, eye disease, and dermatology. The Company has positioned Aptocine to benefit an increasing number of patients with a strong portfolio of intellectual property and innovative applications in development. Light Sciences Oncology Pharmaceuticals & Biotechnology
private:lightsciencesoncology 44861 Feb 16th, 2018 12:00AM Light Sciences Oncology 413 14.00 Open Pharmaceuticals Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM Light Sciences Oncology (LSO) is developing Aptocine™ (talaporfin sodium) for the treatment of solid tumors as well as other indications such as benign prostatic hyperplasia (BPH). Aptocine is a water-soluble drug energized by a small, single-use, disposable drug activator included with the drug. Aptocine is designed to provide tolerable, effective, and repeatable treatments for patients. LSO has completed treatment in Phase 3 trials of Aptocine in patients with hepatocellular carcinoma (HCC) and patients with metastatic colorectal cancer (MCRC). LSO is also conducting clinical trials of Aptocine in benign prostatic hyperplasia (BPH), or enlargement of the prostate, and is supporting a trial of Aptocine in neurofibromatosis, and has clinical or preclinical programs in cardiovascular disease, eye disease, and dermatology. The Company has positioned Aptocine to benefit an increasing number of patients with a strong portfolio of intellectual property and innovative applications in development. Light Sciences Oncology Pharmaceuticals & Biotechnology
private:lightsciencesoncology 44861 Feb 15th, 2018 12:00AM Light Sciences Oncology 413 14.00 Open Pharmaceuticals Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM Light Sciences Oncology (LSO) is developing Aptocine™ (talaporfin sodium) for the treatment of solid tumors as well as other indications such as benign prostatic hyperplasia (BPH). Aptocine is a water-soluble drug energized by a small, single-use, disposable drug activator included with the drug. Aptocine is designed to provide tolerable, effective, and repeatable treatments for patients. LSO has completed treatment in Phase 3 trials of Aptocine in patients with hepatocellular carcinoma (HCC) and patients with metastatic colorectal cancer (MCRC). LSO is also conducting clinical trials of Aptocine in benign prostatic hyperplasia (BPH), or enlargement of the prostate, and is supporting a trial of Aptocine in neurofibromatosis, and has clinical or preclinical programs in cardiovascular disease, eye disease, and dermatology. The Company has positioned Aptocine to benefit an increasing number of patients with a strong portfolio of intellectual property and innovative applications in development. Light Sciences Oncology Pharmaceuticals & Biotechnology
private:lightsciencesoncology 44861 Feb 14th, 2018 12:00AM Light Sciences Oncology 413 14.00 Open Pharmaceuticals Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM Light Sciences Oncology (LSO) is developing Aptocine™ (talaporfin sodium) for the treatment of solid tumors as well as other indications such as benign prostatic hyperplasia (BPH). Aptocine is a water-soluble drug energized by a small, single-use, disposable drug activator included with the drug. Aptocine is designed to provide tolerable, effective, and repeatable treatments for patients. LSO has completed treatment in Phase 3 trials of Aptocine in patients with hepatocellular carcinoma (HCC) and patients with metastatic colorectal cancer (MCRC). LSO is also conducting clinical trials of Aptocine in benign prostatic hyperplasia (BPH), or enlargement of the prostate, and is supporting a trial of Aptocine in neurofibromatosis, and has clinical or preclinical programs in cardiovascular disease, eye disease, and dermatology. The Company has positioned Aptocine to benefit an increasing number of patients with a strong portfolio of intellectual property and innovative applications in development. Light Sciences Oncology Pharmaceuticals & Biotechnology
private:lightsciencesoncology 44861 Feb 13th, 2018 12:00AM Light Sciences Oncology 413 14.00 Open Pharmaceuticals Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM Light Sciences Oncology (LSO) is developing Aptocine™ (talaporfin sodium) for the treatment of solid tumors as well as other indications such as benign prostatic hyperplasia (BPH). Aptocine is a water-soluble drug energized by a small, single-use, disposable drug activator included with the drug. Aptocine is designed to provide tolerable, effective, and repeatable treatments for patients. LSO has completed treatment in Phase 3 trials of Aptocine in patients with hepatocellular carcinoma (HCC) and patients with metastatic colorectal cancer (MCRC). LSO is also conducting clinical trials of Aptocine in benign prostatic hyperplasia (BPH), or enlargement of the prostate, and is supporting a trial of Aptocine in neurofibromatosis, and has clinical or preclinical programs in cardiovascular disease, eye disease, and dermatology. The Company has positioned Aptocine to benefit an increasing number of patients with a strong portfolio of intellectual property and innovative applications in development. Light Sciences Oncology Pharmaceuticals & Biotechnology
private:lightsciencesoncology 44861 Feb 12th, 2018 12:00AM Light Sciences Oncology 413 14.00 Open Pharmaceuticals Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM Light Sciences Oncology (LSO) is developing Aptocine™ (talaporfin sodium) for the treatment of solid tumors as well as other indications such as benign prostatic hyperplasia (BPH). Aptocine is a water-soluble drug energized by a small, single-use, disposable drug activator included with the drug. Aptocine is designed to provide tolerable, effective, and repeatable treatments for patients. LSO has completed treatment in Phase 3 trials of Aptocine in patients with hepatocellular carcinoma (HCC) and patients with metastatic colorectal cancer (MCRC). LSO is also conducting clinical trials of Aptocine in benign prostatic hyperplasia (BPH), or enlargement of the prostate, and is supporting a trial of Aptocine in neurofibromatosis, and has clinical or preclinical programs in cardiovascular disease, eye disease, and dermatology. The Company has positioned Aptocine to benefit an increasing number of patients with a strong portfolio of intellectual property and innovative applications in development. Light Sciences Oncology Pharmaceuticals & Biotechnology
private:lightsciencesoncology 44861 Feb 11th, 2018 12:00AM Light Sciences Oncology 413 14.00 Open Pharmaceuticals Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM Light Sciences Oncology (LSO) is developing Aptocine™ (talaporfin sodium) for the treatment of solid tumors as well as other indications such as benign prostatic hyperplasia (BPH). Aptocine is a water-soluble drug energized by a small, single-use, disposable drug activator included with the drug. Aptocine is designed to provide tolerable, effective, and repeatable treatments for patients. LSO has completed treatment in Phase 3 trials of Aptocine in patients with hepatocellular carcinoma (HCC) and patients with metastatic colorectal cancer (MCRC). LSO is also conducting clinical trials of Aptocine in benign prostatic hyperplasia (BPH), or enlargement of the prostate, and is supporting a trial of Aptocine in neurofibromatosis, and has clinical or preclinical programs in cardiovascular disease, eye disease, and dermatology. The Company has positioned Aptocine to benefit an increasing number of patients with a strong portfolio of intellectual property and innovative applications in development. Light Sciences Oncology Pharmaceuticals & Biotechnology
private:lightsciencesoncology 44861 Feb 10th, 2018 12:00AM Light Sciences Oncology 413 14.00 Open Pharmaceuticals Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM Light Sciences Oncology (LSO) is developing Aptocine™ (talaporfin sodium) for the treatment of solid tumors as well as other indications such as benign prostatic hyperplasia (BPH). Aptocine is a water-soluble drug energized by a small, single-use, disposable drug activator included with the drug. Aptocine is designed to provide tolerable, effective, and repeatable treatments for patients. LSO has completed treatment in Phase 3 trials of Aptocine in patients with hepatocellular carcinoma (HCC) and patients with metastatic colorectal cancer (MCRC). LSO is also conducting clinical trials of Aptocine in benign prostatic hyperplasia (BPH), or enlargement of the prostate, and is supporting a trial of Aptocine in neurofibromatosis, and has clinical or preclinical programs in cardiovascular disease, eye disease, and dermatology. The Company has positioned Aptocine to benefit an increasing number of patients with a strong portfolio of intellectual property and innovative applications in development. Light Sciences Oncology Pharmaceuticals & Biotechnology
private:lightsciencesoncology 44861 Feb 9th, 2018 12:00AM Light Sciences Oncology 413 14.00 Open Pharmaceuticals Feb 9th, 2017 08:57AM Feb 9th, 2017 08:57AM Light Sciences Oncology (LSO) is developing Aptocine™ (talaporfin sodium) for the treatment of solid tumors as well as other indications such as benign prostatic hyperplasia (BPH). Aptocine is a water-soluble drug energized by a small, single-use, disposable drug activator included with the drug. Aptocine is designed to provide tolerable, effective, and repeatable treatments for patients. LSO has completed treatment in Phase 3 trials of Aptocine in patients with hepatocellular carcinoma (HCC) and patients with metastatic colorectal cancer (MCRC). LSO is also conducting clinical trials of Aptocine in benign prostatic hyperplasia (BPH), or enlargement of the prostate, and is supporting a trial of Aptocine in neurofibromatosis, and has clinical or preclinical programs in cardiovascular disease, eye disease, and dermatology. The Company has positioned Aptocine to benefit an increasing number of patients with a strong portfolio of intellectual property and innovative applications in development. Light Sciences Oncology Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.